Patents by Inventor Kaoxiang Sun
Kaoxiang Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230248732Abstract: Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.Type: ApplicationFiled: April 21, 2023Publication date: August 10, 2023Inventors: Youxin LI, Chunjie SHA, Fengjuan ZHAO, Changbing TU, Kaoxiang SUN, Wanhui LIU, Lifang SUN, Ying MENG
-
Patent number: 11666573Abstract: Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.Type: GrantFiled: October 26, 2018Date of Patent: June 6, 2023Assignee: Geneora Pharma (Shijiazhuang) Co., Ltd.Inventors: Youxin Li, Chunjie Sha, Fengjuan Zhao, Changbing Tu, Kaoxiang Sun, Wanhui Liu, Lifang Sun, Ying Meng
-
Patent number: 11110094Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: July 29, 2019Date of Patent: September 7, 2021Assignees: Shandong Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd.Inventors: Kaoxiang Sun, Rongcai Liang, Oilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Publication number: 20200297729Abstract: Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.Type: ApplicationFiled: October 26, 2018Publication date: September 24, 2020Inventors: Youxin LI, Chunjie SHA, Fengjuan ZHAO, Changbing TU, Kaoxiang SUN, Wanhui LIU, Lifang SUN, Ying MENG
-
Publication number: 20190343840Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: ApplicationFiled: July 29, 2019Publication date: November 14, 2019Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 10406161Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: September 27, 2018Date of Patent: September 10, 2019Assignees: SHANDONG LUYE PHARMACEUTICAL CO., LTD., NANJING LUYE PHARMACEUTICAL CO., LTD.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 10258572Abstract: A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly (lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.Type: GrantFiled: October 20, 2017Date of Patent: April 16, 2019Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Wei Sun, Xuemei Zhang, Tao Wang, Guangyi Leng, Kaoxiang Sun, Youxin Li, Wanhui Liu
-
Publication number: 20190022098Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: ApplicationFiled: September 27, 2018Publication date: January 24, 2019Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 10098882Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: November 9, 2016Date of Patent: October 16, 2018Assignees: Shandong Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Publication number: 20180036246Abstract: A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly (lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.Type: ApplicationFiled: October 20, 2017Publication date: February 8, 2018Applicant: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Wei Sun, Xuemei Zhang, Tao Wang, Guangyi Leng, Kaoxiang Sun, Youxin Li, Wanhui Liu
-
Publication number: 20170056407Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: ApplicationFiled: November 9, 2016Publication date: March 2, 2017Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 9532991Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: July 22, 2016Date of Patent: January 3, 2017Assignees: Shandong Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., LtdInventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Publication number: 20160331752Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: ApplicationFiled: July 22, 2016Publication date: November 17, 2016Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 9446135Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: April 10, 2012Date of Patent: September 20, 2016Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 9265835Abstract: The disclosure relates to a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.Type: GrantFiled: November 25, 2011Date of Patent: February 23, 2016Assignee: SHAN DONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Youxin Li, Aiping Wang, Wanhui Liu, Kaoxiang Sun, Jun Li, Lifang Sun
-
Publication number: 20160022584Abstract: A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly(lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.Type: ApplicationFiled: October 8, 2015Publication date: January 28, 2016Applicant: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Wei Sun, Xuemei Zhang, Tao Wang, Guangyi Leng, Kaoxiang Sun, Youxin Li, Wanhui Liu
-
Publication number: 20140377369Abstract: The disclosure relates to a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.Type: ApplicationFiled: November 25, 2011Publication date: December 25, 2014Inventors: Youxin LI, Aiping WANG, Wanhui LIU, Kaoxiang SUN, Jun LI, Lifang SUN
-
Publication number: 20140356442Abstract: Sustained release triptorelin microspheres include triptorelin or a salt of triptorelin, a copolymer of lactide and glycolide, and glucose or mannitol. The sustained release triptorelin microspheres have a relatively high initial release after administration, which allows the drug to produce its pharmaceutical effects immediately and to maintain long-term steady pharmaceutical effects.Type: ApplicationFiled: December 18, 2012Publication date: December 4, 2014Applicant: Shangdong Luye Pharmaceutical Co., Ltd.Inventors: Kaoxiang Sun, Tao Song, Qilin Wang, Jie Han, Tao Wang, Jiangbin Han, Jianzhao Zhang, Shujiang Wang
-
Publication number: 20140050799Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: ApplicationFiled: April 10, 2012Publication date: February 20, 2014Applicant: SHANDONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Publication number: 20130309314Abstract: The disclosure provides a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.Type: ApplicationFiled: November 25, 2011Publication date: November 21, 2013Inventors: Youxin Li, Aiping Wang, Wanhui Liu, Kaoxiang Sun, Jun Li, Lifang Sun